Jury Hands $142M Win To Kaiser In Neurontin Battle
A federal jury has found that Pfizer Inc. improperly marketed its epilepsy drug Neurontin in violation of racketeering and competition laws, awarding plaintiff Kaiser Foundation Health Plan Inc. over $142 million....To view the full article, register now.
Already a subscriber? Click here to view full article